Esperion's Upcoming Participation in BioConnect Investor Conference
ANN ARBOR, Mich. — Esperion (NASDAQ: ESPR) recently announced its upcoming participation in the H.C. Wainwright’s 3rd Annual BioConnect Investor Conference. The event is scheduled for May 20 and begins at 10 a.m. ET. This conference allows Esperion to engage with investors and share insights about their innovative approaches in biopharmaceuticals.
Accessing the Live Webcast
Investors and interested parties can tune into the live webcast directly through the investor section of the Esperion website. Access to a replay of the event will be available shortly after the session concludes, with the recorded details accessible for about 90 days.
About Esperion Therapeutics
Esperion Therapeutics, Inc. operates as a commercial-stage biopharmaceutical company dedicated to addressing significant healthcare needs. Their primary focus is the development and commercialization of the first FDA-approved oral medication aimed at reducing low-density lipoprotein cholesterol (LDL-C), an essential task for patients at risk of cardiovascular disease. Backed by nearly 14,000 patients involved in the CLEAR Cardiovascular Outcomes Trial, these innovative treatments signify a major breakthrough in cardiology.
Innovations in LDL-C Treatment
The company's advancements in treating elevated LDL-C highlight their commitment to bridging gaps in existing healthcare solutions. By developing non-statin oral medications, Esperion provides new options to patients who have struggled with traditional therapies. These efforts are just a part of Esperion's broader mission to enhance patient care.
Future Directions for Esperion
As Esperion progresses, it continues to expand its horizons by developing next-generation treatments targeting ATP citrate lyase inhibitors (ACLYi). These innovative insights into ACLYi have paved the way for crafting highly specific and effective inhibitors, a nod to their progressing drug design capabilities. Such advancements not only solidify their research but also support the potential for even more impactful cardiovascular therapies in the future.
Building a Stronger Global Presence
Esperion's commitment to evolving as a global biopharmaceutical leader is manifested through strategic commercial execution and expansion of international partnerships. Collaboration plays a crucial role in advancing their pre-clinical pipeline, further strengthening their diverse portfolio of therapeutic options.
Get to Know Esperion Better
To dive deeper into what Esperion has to offer, potential investors and interested parties can visit the company’s official website. Here, they’ll find not only information about their current projects but also updates on their innovative pipeline and corporate developments.
Contact Information for Investors and Media
Investors seeking more details may reach out to Alina Venezia at investorrelations@esperion.com or call (734) 887-3903. For media inquiries, Tiffany Aldrich is available at corporateteam@esperion.com or by calling (616) 443-8438.
Frequently Asked Questions
What is the main focus of Esperion Therapeutics?
Esperion focuses on developing innovative oral therapies for patients with elevated LDL-C to address cardiovascular risks.
When does the H.C. Wainwright Investor Conference take place?
The conference is scheduled for May 20 at 10 a.m. ET.
How can I access the webcast of the conference?
The webcast can be accessed through the investor section on the Esperion website.
Who can I contact for investor-related inquiries?
Investors can reach Alina Venezia at investorrelations@esperion.com or by phone at (734) 887-3903.
What future developments is Esperion focused on?
Esperion is working on next-generation treatments involving ACLYi to enhance their therapeutic offerings further.